

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2022/159653 A8

(43) International Publication Date
28 July 2022 (28.07.2022)

(51) International Patent Classification:
C07K 14/705 (2006.01)

(21) International Application Number:
PCT/US2022/013231

(22) International Filing Date:
21 January 2022 (21.01.2022)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/140,752 22 January 2021 (22.01.2021) US

(71) Applicant: **ELPIS BIOPHARMACEUTICALS**
[US/US]; 128 Spring Street, Lexington, Massachusetts
02421 (US).

(72) Inventors: **CHEN, Yan**; c/o Elpis Biopharmaceuticals,
128 Spring Street, Lexington, Massachusetts 02421 (US).
NGUYEN, Jenna; c/o Elpis Biopharmaceuticals, 128
Spring Street, Lexington, Massachusetts 02421 (US).
ZHAO, Kehao; c/o Elpis Biopharmaceuticals, 128 Spring

Street, Lexington, Massachusetts 02421 (US). **ZHANG, Keming**; c/o Elpis Biopharmaceuticals, 128 Spring Street, Lexington, Massachusetts 02421 (US).

(74) Agent: **CHEN, Yahua**; c/o McDermott Will & Emery LLP,
500 North Capitol Street, NW, Washington, District of Co-
lumbia 20001 (US).


(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,

(54) Title: BISPECIFIC CHIMERIC ANTIGEN RECEPTORS BINDING TO CD19 AND CD22

FIG. 1

CD19 and CD22 receptor counts by qFlow



(57) Abstract: Bi-specific chimeric antigen receptors (CARs) capable of binding to both CD19 and CD22 and immune cells expressing such. Also provided herein are therapeutic uses of such immune cells (e.g., CAR-T cells) for eliminating disease cells such as cancer cells.

[Continued on next page]

UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*

(48) Date of publication of this corrected version:

16 February 2023 (16.02.2023)

(15) Information about Correction:

see Notice of 16 February 2023 (16.02.2023)